BridgeBio Posted Q2 Revenue Beat, but Faces Higher Near‑Term Launch Opex, Morgan Stanley Says

BridgeBio Pharma's Q2 2026 revenue of $243.7 million exceeded analyst expectations of about $220.9 million, beating estimates by roughly $22.7 million and representing a 120% year‑over‑year increase, largely driven by $222.4 million in U.S. net product sales of Attruby for ATTR‑CM.

Despite the revenue beat, BridgeBio reported a wider‑than‑expected loss of $0.78 per share versus consensus of about $0.58–$0.60, reflecting higher operating expenses tied to launching and expanding its franchise.

Morgan Stanley acknowledged the strong revenue growth and beat but highlighted an elevated near‑term launch opex profile, which may pressure margins and delay profitability despite the robust top‑line performance.

Coverage from Morgan Stanley and other analysts notes that the beat is underpinned by the launch momentum of Attruby, favorable pricing and uptake in the ATTR‑CM market, and growing royalty income, while the raised launch‑related costs reflect accelerated commercialization and pipeline investments.